Eisai Co (ESALF)
Eisai Co., Ltd. is a Japanese pharmaceutical company whose American depositary receipt is listed over the counter on OTC Markets under the ticker ESALF. The company is involved in the research, development, manufacturing, and sale of medicines in Japan, with additional operations across Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, and the Global South. Its business is organized around pharmaceuticals and related segments, with a focus on neurology, oncology, and other therapeutic areas. Eisai’s portfolio includes Lenvima, an oncology treatment; LEQEMBI, an anti-amyloid-beta monoclonal antibody; and Dayvigo, a prescription medicine. The company also sells prescription and over-the-counter drugs. Founded in 1941 and headquartered in Tokyo, it adopted its current name in 1955.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ESAL.F
|
—
|
—
|
—
|
—
|
—
|
—
|
Good
|
—
|
—
|
—
|
3.8%
|
August 3, 2026
|
32.6x
|
1.4x
|
1.5x
|
7.776 B
|
7.256 B
|
34.6%
|
99.7%
|
9.4
|
117.1%
|
119.2%
|
